A Phase 3 interventional study of Angioplasty of all peripheral AVF stenosis in Arteriovenous Fistula, Arteriovenous Fistula Stenosis and Dialysis Access Malfunction, sponsored by Singapore General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-08-14.
Sponsored by Singapore General Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Arteriovenous Fistula with a site in Singapore — 1 open to participants now, 1 under way, 1 of them phase 3. Arteriovenous Fistula · Singapore.
Among the 11 studies in Arteriovenous Fistula with a site in Singapore, this one is the only one that started in 2024, is the only one in phase 3, and was the 11th registered.
248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.
Browse Arteriovenous Fistula studies →1 of the 11 studies in Arteriovenous Fistula with a site in Singapore is open now.
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 94 is above the median of 64 across 166 interventional studies indexed under Arteriovenous Fistula.
Median enrollment 50 across the 7 interventional studies, 70 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 5 most frequent:
Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Singapore General Hospital has 7 studies filed under Arteriovenous Fistula — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Arteriovenous Fistula with a site in Singapore, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the access circuit primary patency after Ranger drug-coated balloon angioplasty of arteriovenous fistula (AVF) stenosis with that after conventional balloon angioplasty
This is a blinded randomized controlled trial recruiting 94 patients with AVF stenosis who will be randomized in a 1:1 ratio to either drug-coated balloon (Ranger) or conventional balloon. All peripheral AVF stenoses will be treated with the allocated balloon type.
The primary outcome measure is 6-month access circuit patency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranger drug-coated balloon will be used for all peripheral AVF stenosis.
Device: Angioplasty of all peripheral AVF stenosis
Conventional balloon will be used for all peripheral AVF stenosis.
Device: Angioplasty of all peripheral AVF stenosis
All peripheral AVF stenosis are to be treated with the same type of balloon depending on allocation
Access circuit primary patency
Time to next clinically-driven intervention
Time frame: 6 months
Access access circuit patency
Time to next clinically-driven intervention
Time frame: 12 months
Access circuit assisted primary patency
Time to next access thrombosis or surgical intervention.
Time frame: 6 and 12 months
Access circuit secondary patency
Time to access abandonment or surgical revision / declotting
Time frame: 6 and 12 months
Procedural complication
Complication related to procedure
Time frame: 12 months
Mortality
All cause mortality
Time frame: 12 months and 5 years
Plan to share: Undecided
Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.